Docetaxel Followed by Provenge in Metastatic Prostate Cancer

NCT02793765 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Dendreon was sold and new company decided not to fund study.

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel
BIOLOGICAL: Sipuleucel-T

Sponsor

The University of Texas Health Science Center, Houston